<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Management of chronic hepatitis C virus infection: Initial antiviral therapy in adults</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Management of chronic hepatitis C virus infection: Initial antiviral therapy in adults</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Management of chronic hepatitis C virus infection: Initial antiviral therapy in adults</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Andrew J Muir, MD, MHS</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Camilla S Graham, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Adrian M Di Bisceglie, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Allyson Bloom, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jan 24, 2024.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H148833304"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Hepatitis C virus (HCV) can cause both acute and chronic hepatitis. The acute process is self-limited, rarely causes hepatic failure, and usually leads to chronic infection. Chronic HCV infection often follows a progressive course over many years and can ultimately result in cirrhosis, hepatocellular carcinoma, and the need for liver transplantation. (See  <a class="medical medical_review" href="/d/html/3672.html" rel="external">"Clinical manifestations and natural history of chronic hepatitis C virus infection"</a>.)</p><p>Successful antiviral treatment of chronic HCV infection halts the progression of liver disease and is associated with improvement in liver-related morbidity and mortality. This topic will review the antiviral selection and administration for initial therapy of chronic HCV infection.</p><p>Our recommendations are generally consistent with joint guidelines on HCV management from the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA), which can be accessed at <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.hcvguidelines.org%2F&amp;token=sL%2Bp%2BgWoM5K8OZ3TcR7z2aLRyWCGNBK9vbXZNzy9A7wOhWa41Lo4fh2xvvlb%2BhyX&amp;TOPIC_ID=16592" target="_blank">www.hcvguidelines.org</a> [<a href="#rid1">1,2</a>]. </p><p>Management issues other than initial antiviral selection for chronic HCV infection are discussed elsewhere: </p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3673.html" rel="external">"Overview of the management of chronic hepatitis C virus infection"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/15832.html" rel="external">"Patient evaluation and selection for antiviral therapy for chronic hepatitis C virus infection"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/15795.html" rel="external">"Management of chronic hepatitis C virus infection: Antiviral retreatment following relapse in adults"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/d/html/3650.html" rel="external">"Clinical manifestations, diagnosis, and treatment of acute hepatitis C virus infection in adults"</a>.)</p><p></p><p class="headingAnchor" id="H762952578"><span class="h1">GENERAL PRINCIPLES</span></p><p class="headingAnchor" id="H3662491638"><span class="h2">Treatment objective</span><span class="headingEndMark"> — </span>We recommend antiviral treatment for all patients with chronic HCV infection. The clinical objective of HCV treatment is cure of the infection. In the clinical setting and in HCV treatment trials, the marker for treatment success is a sustained virologic response (SVR), which is defined as an undetectable HCV viral level 12 weeks after the completion of therapy. An SVR at this time period has been associated with a &gt;99 percent chance of sustained clearance of HCV, an effective cure of HCV infection [<a href="#rid3">3</a>]. SVR has also been associated with patient-important outcomes such as decreased mortality, decreased liver-related complications, and improved quality of life. These issues are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/15832.html" rel="external">"Patient evaluation and selection for antiviral therapy for chronic hepatitis C virus infection", section on 'Benefits of treatment'</a>.) </p><p class="headingAnchor" id="H3117942370"><span class="h2">Prioritizing access to therapy</span><span class="headingEndMark"> — </span>A major barrier to achieving SVR and HCV cure is access to therapy. This may be related to limited access to pretreatment testing or monitoring in resource-constrained or nontraditional care settings, nonspecialty provider unfamiliarity with treatment options, concern that patients may not return for follow up visits, or payor restrictions. Given the high efficacy rates of contemporary antiviral regimens for initial therapy of HCV infection, regardless of genotype and the presence of compensated cirrhosis, we favor a simplified approach that may circumvent some of these limitations. This includes:</p><p class="bulletIndent1"><span class="glyph">●</span>A streamlined approach to regimen selection with limited pretreatment evaluation (see <a class="local">'Limited pretreatment evaluation'</a> below)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A minimalist approach to monitoring (see <a class="local">'Potential for minimal monitoring during treatment'</a> below)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A low threshold to offer therapy despite unstable housing or active injection drug use (see  <a class="medical medical_review" href="/d/html/15832.html" rel="external">"Patient evaluation and selection for antiviral therapy for chronic hepatitis C virus infection", section on 'Active drug use'</a>) </p><p></p><p>Data suggest that a simplified approach to care does not compromise the success of initial treatment [<a href="#rid4">4</a>]. High SVR rates can be achieved among patients treated by nonspecialists (including primary care physicians, nurse practitioners, and pharmacists) [<a href="#rid5">5,6</a>], without on-treatment monitoring [<a href="#rid4">4,7</a>], and despite injection drug use [<a href="#rid8">8</a>]. </p><p class="headingAnchor" id="H2278357921"><span class="h2">Limited pretreatment evaluation</span><span class="headingEndMark"> — </span>Prior to regimen selection for initial HCV therapy, limited pretreatment evaluation includes: </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Assessment for cirrhosis</strong> – This entails assessment through history, examination, and basic laboratory testing. If readily available, noninvasive testing for cirrhosis can also identify advanced fibrosis or cirrhosis. However, since the initial treatment regimens are largely the same for those with and without compensated cirrhosis, non-invasive tests for fibrosis are not essential to making treatment decisions, as long as there is no clinical suspicion for decompensated cirrhosis (eg, ascites, history of varices, hepatic encephalopathy). Although not necessary for determining treatment regimens, identifying advance fibrosis or cirrhosis remains important for clinical care, as these patients require ongoing surveillance for hepatocellular carcinoma. The clinical evaluation for cirrhosis is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/15832.html" rel="external">"Patient evaluation and selection for antiviral therapy for chronic hepatitis C virus infection", section on 'Assessment of fibrosis stage'</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluating for other conditions that might impact management</strong> – These include testing for HIV, hepatitis B virus (HBV) infection, and pregnancy. Additionally, reviewing all the medications the patient is taking (prescription, over-the-counter, and herbal medications) is important to inform the potential for drug interactions. These are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/15832.html" rel="external">"Patient evaluation and selection for antiviral therapy for chronic hepatitis C virus infection", section on 'Evaluation for comorbidities or conditions that might affect therapy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Optional genotype testing</strong> – For initial therapy, knowledge of the HCV genotype is not necessary for regimen selection, and we do not routinely check it. Lack of genotype testing results should not be a barrier to HCV treatment. (See  <a class="medical medical_review" href="/d/html/15832.html" rel="external">"Patient evaluation and selection for antiviral therapy for chronic hepatitis C virus infection", section on 'HCV genotype in selected cases'</a>.)</p><p></p><p>Having to check a genotype may not be easily accessible in non-traditional care sites or lead to delays in care. On the other hand, if genotype testing is readily available and will not impede access to or delay treatment, it is reasonable to check it. In some cases (specifically, for patients who have cirrhosis and genotype 3 infection), knowledge of the genotype may allow for more specific regimen selection that could result in slightly higher SVR rates. Documentation of the baseline genotype can also help distinguish relapse versus reinfection if patients are found to have HCV viremia after treatment, although making this distinction is not always necessary. (See  <a class="medical medical_review" href="/d/html/15795.html" rel="external">"Management of chronic hepatitis C virus infection: Antiviral retreatment following relapse in adults", section on 'Distinguishing relapse from reinfection'</a>.)</p><p class="headingAnchor" id="H1658212657"><span class="h1">PATIENTS WITHOUT KNOWN CIRRHOSIS</span><span class="headingEndMark"> — </span>Initial HCV therapy for patients without cirrhosis can generally be selected without knowledge of the genotype. </p><p class="headingAnchor" id="H2716456006"><span class="h2">Our preferred regimens</span></p><p class="headingAnchor" id="H4260925382"><span class="h3">Selecting among preferred regimens</span><span class="headingEndMark"> — </span>For initial therapy of chronic HCV infection, we recommend one of the following direct-acting antiviral (DAA) regimens  (<a class="graphic graphic_algorithm graphicRef93587" href="/d/graphic/93587.html" rel="external">algorithm 1</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="108951" href="/d/drug information/108951.html" rel="external">Sofosbuvir-velpatasvir</a> for 12 weeks (see <a class="local">'Sofosbuvir-velpatasvir'</a> below)</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="114296" href="/d/drug information/114296.html" rel="external">Glecaprevir-pibrentasvir</a> for 8 weeks (see <a class="local">'Glecaprevir-pibrentasvir'</a> below)</p><p></p><p>These two regimens have very high efficacy regardless of genotype and good safety profiles. Although they have not been compared directly, they have each resulted in sustained virologic response (SVR) rates in excess of 95 percent among individuals undergoing initial HCV antiviral therapy and are reasonably expected to have similar effectiveness. </p><p>The choice between them is primarily limited by availability; in the United States, some payers will only provide coverage for a single preferred regimen. If both are options, the choice depends on potential for drug interactions and patient preference:</p><p class="bulletIndent1"><span class="glyph">●</span>Drug interactions with each are generally manageable but should be evaluated prior to initiation. For other specific drug interactions, refer to the <a class="external" href="/drug-interactions">drug interactions program</a> included with UpToDate. Specific drug interactions are discussed below and in the <a class="external" href="/drug-interactions">drug interactions program</a> included with UpToDate. (See <a class="local">'Sofosbuvir-velpatasvir'</a> below and <a class="local">'Glecaprevir-pibrentasvir'</a> below.)</p><p></p><p class="bulletIndent1">Rare drugs (eg, <a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">carbamazepine</a> and <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a>) are not recommended for co-administration with either option. Patients taking such drugs should be managed in consultation with a specialist; a potential approach is switching the medication that interacts with the DAAs to a different option. Data on co-administration with such drugs are extremely limited [<a href="#rid9">9,10</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Administration differences may impact patient choice. <a class="drug drug_general" data-topicid="108951" href="/d/drug information/108951.html" rel="external">Sofosbuvir-velpatasvir</a> is given as a single combination tablet once daily with or without food for 12 weeks, whereas <a class="drug drug_general" data-topicid="114296" href="/d/drug information/114296.html" rel="external">glecaprevir-pibrentasvir</a> is given as three combination tablets once daily with food for 8 weeks. Some patients prioritize the shorter regimen duration, whereas others prefer the simplicity of a single pill. Some patients do not have a regular meal schedule and thus prefer a regimen that can be taken without regard to food.</p><p></p><p class="bulletIndent1">In the United States, each daily dose of <a class="drug drug_general" data-topicid="114296" href="/d/drug information/114296.html" rel="external">glecaprevir-pibrentasvir</a> is packaged in a separate box, so the monthly supply is bulky. <a class="drug drug_general" data-topicid="108951" href="/d/drug information/108951.html" rel="external">Sofosbuvir-velpatasvir</a> is available in a bottle containing the monthly supply of 28 tablets. Patients, particularly those with unstable housing and limited storage options, may have a practical preference between the packaging. </p><p></p><p>Although the joint American Association for the Study of Liver Diseases (AASLD)/Infectious Diseases Society of America (IDSA) guidelines label other regimens (<a class="drug drug_general" data-topicid="97562" href="/d/drug information/97562.html" rel="external">ledipasvir-sofosbuvir</a> for genotypes 1, 4, 5, and 6; <a class="drug drug_general" data-topicid="106574" href="/d/drug information/106574.html" rel="external">elbasvir-grazoprevir</a> for genotypes 1b and 4) as preferred, we almost never use them since they offer no clear advantage over the preferred pangenotypic regimens and using them optimally may require additional testing that could be a barrier to care. Occasionally, payers may suggest one of these alternative regimens. These regimens are discussed elsewhere. (See <a class="local">'Alternative regimens'</a> below.)</p><p class="headingAnchor" id="H1723633731"><span class="h3">Sofosbuvir-velpatasvir</span><span class="headingEndMark"> — </span>For the vast majority of patients with chronic HCV infection, the pangenotypic regimen of <a class="drug drug_general" data-topicid="108951" href="/d/drug information/108951.html" rel="external">sofosbuvir-velpatasvir</a> is one of our preferred antiviral regimens for initial treatment. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing and administration</strong> – It is available as a fixed-dose combination tablet of the NS5B inhibitor <a class="drug drug_general" data-topicid="91794" href="/d/drug information/91794.html" rel="external">sofosbuvir</a> (400 mg) and the NS5A inhibitor velpatasvir (100 mg) and is administered once daily with or without food for 12 weeks. It can be used in patients with any degree of renal or hepatic impairment. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – Support for <a class="drug drug_general" data-topicid="108951" href="/d/drug information/108951.html" rel="external">sofosbuvir-velpatasvir</a> comes from several trials that have demonstrated very high efficacy for initial therapy of all genotypes (SVR rates 95 to 100 percent) [<a href="#rid11">11-17</a>] and from real world observational data that match trial findings [<a href="#rid18">18</a>]. Although some studies suggest a numerically lower SVR rate for patients with genotype 3, the response rate remains very high for that genotype. </p><p></p><p class="bulletIndent1">As an example, in a randomized, placebo-controlled trial that included 624 patients with genotype 1, 2, 4, 5, or 6 who received <a class="drug drug_general" data-topicid="108951" href="/d/drug information/108951.html" rel="external">sofosbuvir-velpatasvir</a> for 12 weeks, the overall SVR rate was 99 percent compared with 0 percent among the 116 patients who received placebo [<a href="#rid11">11</a>]. In two other randomized trials, sofosbuvir-velpatasvir resulted in superior SVR rates among 266 patients with genotype 2 infection (99 versus 94 percent, absolute difference 5.2 percent, 95% CI 0.2-10.3) and 552 patients with genotype 3 infection (95 versus 80 percent, absolute difference 14.8 percent, 95% CI 9.6-20) compared with <a class="drug drug_general" data-topicid="91794" href="/d/drug information/91794.html" rel="external">sofosbuvir</a> plus <a class="drug drug_general" data-topicid="9860" href="/d/drug information/9860.html" rel="external">ribavirin</a> for 12 weeks, which had been the previously recommended regimens for those genotypes [<a href="#rid14">14</a>]. Among the 197 patients with genotype 3 infection who did not have cirrhosis, the SVR rate with sofosbuvir-velpatasvir was 97 percent [<a href="#rid14">14</a>]. In all three trials, virologic failure (either failure to suppress on therapy or relapse after therapy) was only identified in 2 of 328 patients with genotype 1 infection (&lt;1 percent) and in 11 of 277 patients with genotype 3 infection (4 percent); other reasons for failure to achieve SVR included loss to follow up, treatment discontinuation, and consent withdrawal. These trials included patients with and without compensated cirrhosis as well as patients undergoing antiviral therapy for the first time and those who had failed prior interferon-based therapy. </p><p></p><p class="bulletIndent1">Certain genotype 3 subtypes are associated with lower SVR rates with <a class="drug drug_general" data-topicid="108951" href="/d/drug information/108951.html" rel="external">sofosbuvir-velpatasvir</a>. In a multinational trial in Asia, the SVR rate was only 89 percent among the 28 patients with genotype 3b, a subtype identified in that area but rare elsewhere [<a href="#rid16">16</a>]. </p><p></p><p class="bulletIndent1">Similarly high SVR rates overall were reported in an analysis of 12 cohorts from different clinical settings North America and Europe [<a href="#rid18">18</a>]. Among 5196 patients who received <a class="drug drug_general" data-topicid="108951" href="/d/drug information/108951.html" rel="external">sofosbuvir-velpatasvir</a> for 12 weeks, SVR rates were 99.1 percent for genotype 1, 99.3 percent for genotype 2, 98.3 percent for genotype 3, 99.6 percent for genotype 4, and 98.5 percent for genotypes 5 and 6.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Potential drug interactions</strong> – Coadministration is not recommended with <a class="drug drug_general" data-topicid="8595" href="/d/drug information/8595.html" rel="external">amiodarone</a>, certain anticonvulsants (eg, <a class="drug drug_general" data-topicid="9769" href="/d/drug information/9769.html" rel="external">phenytoin</a>, <a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">carbamazepine</a>, <a class="drug drug_general" data-topicid="9763" href="/d/drug information/9763.html" rel="external">phenobarbital</a>, <a class="drug drug_general" data-topicid="9467" href="/d/drug information/9467.html" rel="external">oxcarbazepine</a>), rifamycins, certain HIV antiretrovirals (eg, <a class="drug drug_general" data-topicid="8731" href="/d/drug information/8731.html" rel="external">efavirenz</a>), and St. John’s wort. </p><p></p><p class="bulletIndent1">Additionally, increased gastric pH levels decrease absorption of velpatasvir; thus, coadministration with proton pump inhibitors is ideally avoided. However, if necessary, <a class="drug drug_general" data-topicid="9718" href="/d/drug information/9718.html" rel="external">omeprazole</a> 20 mg can be coadministered, with <a class="drug drug_general" data-topicid="108951" href="/d/drug information/108951.html" rel="external">sofosbuvir-velpatasvir</a> taken with food and four hours prior to the omeprazole dose [<a href="#rid19">19</a>]; the use with other proton pump inhibitors in this way has not been studied, and we avoid it. We also counsel patients to avoid over-the-counter products that may contain stomach acid neutralizers until they discuss it with a clinician. If they cannot stop taking antacids or H2-receptor antagonists during the course of HCV treatment, they can cautiously take them at least four hours following the sofosbuvir-velpatasvir dose. We carefully counsel any patient continuing to take an acid-reducing medication in this way to ensure they understand the importance of the timing of administration.</p><p></p><p class="bulletIndent1">For other specific drug interactions, refer to the <a class="external" href="/drug-interactions">drug interactions program</a> included with UpToDate.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects </strong>– <a class="drug drug_general" data-topicid="108951" href="/d/drug information/108951.html" rel="external">Sofosbuvir-velpatasvir</a> is well tolerated, with &lt;1 percent of trial participants discontinuing a 12-week regimen for adverse events. The most common adverse events are fatigue, headache, nausea, nasopharyngitis, and insomnia [<a href="#rid11">11,14,20</a>].</p><p></p><p class="bulletIndent1">Additional details on the dosing, adverse effects, and drug interactions of <a class="drug drug_general" data-topicid="108951" href="/d/drug information/108951.html" rel="external">sofosbuvir-velpatasvir</a> are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/93242.html" rel="external">"Direct-acting antivirals for the treatment of hepatitis C virus infection", section on 'Sofosbuvir-velpatasvir'</a>.)</p><p></p><p class="headingAnchor" id="H3395215005"><span class="h3">Glecaprevir-pibrentasvir</span><span class="headingEndMark"> — </span>For the vast majority of patients with chronic HCV infection, the pangenotypic regimen of <a class="drug drug_general" data-topicid="114296" href="/d/drug information/114296.html" rel="external">glecaprevir-pibrentasvir</a> is one of our preferred antiviral regimens for initial treatment. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dosing and administration</strong> – It is available as a fixed-dose combination of the NS3/4A protease inhibitor glecaprevir (300 mg) and the NS5A inhibitor pibrentasvir (120 mg) and is administered as three tablets once daily with food for eight weeks. It can be used in patients with any degree of renal impairment but should not be used in patients with decompensated cirrhosis (Child Pugh Class B or C) because of increased drug levels and risk of worsening liver function or failure. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Efficacy</strong> – Support for <a class="drug drug_general" data-topicid="108951" href="/d/drug information/108951.html" rel="external">sofosbuvir-velpatasvir</a> comes from several trials that have demonstrated very high efficacy for initial therapy of all genotypes (SVR rates 95 to 99 percent) [<a href="#rid21">21-27</a>] and from real world observational data that match trial findings [<a href="#rid28">28-30</a>]. Although some studies suggest a numerically lower SVR rate for patients with genotype 3, the response rate remains very high for that genotype. </p><p></p><p class="bulletIndent1">As an example, in a pooled analysis of nine randomized trials comparing <a class="drug drug_general" data-topicid="114296" href="/d/drug information/114296.html" rel="external">glecaprevir-pibrentasvir</a> for 8 versus 12 weeks in 2041 patients without cirrhosis, the 8-week regimen resulted in SVR in 99 percent for genotype 1, 98 percent for genotype 2, 95 percent for genotype 3, 95 percent for genotype 4, 100 percent for genotype 5, and 92 percent for genotype 6 [<a href="#rid31">31</a>]. These SVR rates were similar to those with the 12-week regimen. Among the 965 patients who received the 8-week regimen, virologic failure (either failure to suppress on therapy or relapse after therapy) occurred in only nine (one genotype 1, two genotype 2, and six genotype 3). Other reasons for failure to achieve SVR included loss to follow-up or missing data and treatment discontinuation. Certain genotype 3 subtypes are associated with lower SVR rates with glecaprevir-pibrentasvir; in particular, SVR rates are low for genotype 3b, a subtype identified in Asia but rare elsewhere [<a href="#rid32">32</a>].</p><p></p><p class="bulletIndent1">Similarly high SVR rates were reported in an analysis of 15 unique cohorts from the United States, Europe, and Japan [<a href="#rid28">28</a>]. Among 8583 patients who received <a class="drug drug_general" data-topicid="114296" href="/d/drug information/114296.html" rel="external">glecaprevir-pibrentasvir</a> for eight weeks, SVR rates were 95.7 percent for genotype 1, 97.6 percent for genotype 2, 95 percent for genotype 3, and 99 percent for genotype 4.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Potential drug</strong> <strong>interactions</strong> – Because of expected and observed drug interactions, coadministration is contraindicated with <a class="drug drug_general" data-topicid="9864" href="/d/drug information/9864.html" rel="external">rifampin</a> and <a class="drug drug_general" data-topicid="9353" href="/d/drug information/9353.html" rel="external">atazanavir</a> and not recommended with <a class="drug drug_general" data-topicid="9198" href="/d/drug information/9198.html" rel="external">carbamazepine</a>, oral contraceptive agents, St. John's wort, <a class="drug drug_general" data-topicid="9217" href="/d/drug information/9217.html" rel="external">cyclosporine</a>, and certain other HIV antiretrovirals.</p><p></p><p class="bulletIndent1">For other specific drug interactions, refer to the <a class="external" href="/drug-interactions">drug interactions program</a> included with UpToDate.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Adverse effects</strong> – <a class="drug drug_general" data-topicid="114296" href="/d/drug information/114296.html" rel="external">Glecaprevir-pibrentasvir</a> is well tolerated. In an analysis of pooled data from multiple clinical trials, including over 2000 patients with chronic HCV infection, most adverse effects were mild, with headache and fatigue the most common complaints [<a href="#rid33">33</a>]. Fewer than 0.5 percent of patients discontinued therapy because of adverse effects. Elevations in aminotransferase or bilirubin levels were rare and not clearly related to the drug. </p><p></p><p class="bulletIndent1">Additional details on the dosing, adverse effects, and drug interactions of <a class="drug drug_general" data-topicid="114296" href="/d/drug information/114296.html" rel="external">glecaprevir-pibrentasvir</a> are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/93242.html" rel="external">"Direct-acting antivirals for the treatment of hepatitis C virus infection", section on 'Glecaprevir-pibrentasvir'</a>.) </p><p></p><p class="headingAnchor" id="H149264083"><span class="h2">Alternative regimens</span><span class="headingEndMark"> — </span>The preferred regimens discussed above are widely available in the United States and many other countries. Alternative regimens may be needed for individuals who cannot access preferred options, mainly in countries that have preferred pricing or generic forms for other HCV regimens. </p><p>Internationally, the most widely used alternative regimen is: </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sofosbuvir</strong><strong> plus </strong><strong>daclatasvir</strong> – In open-label trials of patients with genotypes 1, 2, 3, and 4 infection, a once-daily regimen of <a class="drug drug_general" data-topicid="91794" href="/d/drug information/91794.html" rel="external">sofosbuvir</a> plus daclatasvir for 12 weeks resulted in SVR rates of 95 percent or higher [<a href="#rid34">34-36</a>]. Observational data have also supported the efficacy of this regimen [<a href="#rid37">37,38</a>]. </p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="91794" href="/d/drug information/91794.html" rel="external">Sofosbuvir</a> plus daclatasvir are given as two separate tablets. The regimen is not available in the United States. Details on dosing, adverse effects, and drug interactions with sofosbuvir and daclatasvir are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/93242.html" rel="external">"Direct-acting antivirals for the treatment of hepatitis C virus infection", section on 'Daclatasvir'</a> and  <a class="medical medical_review" href="/d/html/93242.html" rel="external">"Direct-acting antivirals for the treatment of hepatitis C virus infection", section on 'Sofosbuvir'</a>.)</p><p></p><p>Other alternatives have very limited role in therapy and are used only if the preferred regimens are not available:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Ledipasvir-sofosbuvir</strong> – This is a once-daily regimen that is given for 12 weeks and is a highly effective option for initial therapy of genotypes 1, 4, 5, and 6 infection (SVR rates greater than 95 percent) [<a href="#rid39">39-45</a>]. For patients who have documented genotype 1 infection and meet certain clinical criteria (noninvasive testing that rules out cirrhosis, viral load &lt;6 million international units/mL, no HIV infection, and fewer than two traditional negative predictors of response [eg, being male, obese]), comparably high SVR rates can be achieved with an eight-week regimen, which may be attractive to some patients [<a href="#rid40">40,46</a>]. However, the genotype testing and complex clinical assessment needed to ensure optimal use outweigh this potential advantage of a more streamlined approach to treatment. Details on the dosing, adverse effects, and drug interactions of ledipasvir and <a class="drug drug_general" data-topicid="91794" href="/d/drug information/91794.html" rel="external">sofosbuvir</a> are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/93242.html" rel="external">"Direct-acting antivirals for the treatment of hepatitis C virus infection", section on 'Ledipasvir-sofosbuvir'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Elbasvir-grazoprevir</strong> – This is a once-daily regimen that is given for 12 weeks and is highly effective for genotypes 1 and 4 infection [<a href="#rid47">47-55</a>]. However, it is not widely available. Additionally, optimal use in patents with genotype 1a infection includes testing for pre-existing NS5A resistance-associated substitutions (RASs), which complicates the treatment approach. Details on the dosing, adverse effects, and drug interactions of <a class="drug drug_general" data-topicid="106574" href="/d/drug information/106574.html" rel="external">elbasvir-grazoprevir</a> are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/93242.html" rel="external">"Direct-acting antivirals for the treatment of hepatitis C virus infection", section on 'Elbasvir-grazoprevir'</a>.)</p><p></p><p class="headingAnchor" id="H1417201209"><span class="h2">Potential for minimal monitoring during treatment</span><span class="headingEndMark"> — </span>Given the availability of antiviral regimens that are highly effective for all genotypes and have good safety profiles, administration of antiviral therapy with minimal on-treatment monitoring is an appropriate approach for certain patients undergoing initial therapy for HCV. These include patients who meet the following criteria: </p><p class="bulletIndent1"><span class="glyph">●</span>No known cirrhosis or hepatocellular carcinoma</p><p class="bulletIndent1"><span class="glyph">●</span>No active HBV coinfection (ie, the HBsAg is negative)</p><p class="bulletIndent1"><span class="glyph">●</span>No concerning symptoms during treatment</p><p class="bulletIndent1"><span class="glyph">●</span>No potential drug interactions that may impact therapy of other conditions (eg, glucose control or anticoagulation)</p><p class="bulletIndent1"><span class="glyph">●</span>Taking one of the preferred regimens (see <a class="local">'Our preferred regimens'</a> above)</p><p></p><p>Minimal monitoring involves prescription or delivery of the full antiviral regimen without planned visits or laboratory testing during the antiviral course. Such patients should return following completion of the course to assess for treatment response. (See  <a class="medical medical_review" href="/d/html/3673.html" rel="external">"Overview of the management of chronic hepatitis C virus infection", section on 'Follow-up after antiviral therapy'</a>.)</p><p>For patients who do not meet criteria for minimal monitoring, on-treatment monitoring includes evaluation for rare adverse effects and is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/3673.html" rel="external">"Overview of the management of chronic hepatitis C virus infection", section on 'Monitoring during antiviral therapy'</a>.)</p><p>A minimal monitoring approach is particularly attractive for HCV treatment in nontraditional settings, such as opioid treatment centers, syringe exchange sites, and remote or resource-limited settings. Non-clinical staff in such settings can also provide counseling and other psychosocial support to enhance adherence.</p><p>The feasibility of such an approach was evaluated in a single-arm trial of 399 treatment-naïve patients who were treated with <a class="drug drug_general" data-topicid="108951" href="/d/drug information/108951.html" rel="external">sofosbuvir-velpatasvir</a> without pre-treatment genotyping, with the entire treatment regimen dispensed at the first visit, without scheduled visits or lab tests, and with remote assessment of adherence at week 4 [<a href="#rid4">4</a>]. The overall SVR rate was 95 percent. Only 4 percent reported a serious adverse event, but none were deemed related to treatment. </p><p>Some data suggest that SVR rates with minimal monitoring may be slightly lower than with traditional monitoring, although this is mainly related to loss to follow-up. In a randomized trial of 380 patients who received <a class="drug drug_general" data-topicid="114296" href="/d/drug information/114296.html" rel="external">glecaprevir-pibrentasvir</a>, the SVR rates among those who had limited clinic follow-up (at baseline and post-treatment, with nursing calls at weeks 4 and 8) was 92 percent, compared with 95 percent among those who also had clinic follow-up at weeks 4 and 8 with on-treatment testing (SVR difference -3.2 percent, 95% CI -8.2-1.8) [<a href="#rid7">7</a>]. After excluding participants who were lost to follow up or had missing data, SVR rates were 97 and 98 percent. </p><p class="headingAnchor" id="H1542875570"><span class="h1">PATIENTS WITH KNOWN CIRRHOSIS</span></p><p class="headingAnchor" id="H1040331147"><span class="h2">Compensated cirrhosis (Child-Pugh class A)</span></p><p class="headingAnchor" id="H722328365"><span class="h3">Antiviral regimen selection</span><span class="headingEndMark"> — </span>For patients with compensated cirrhosis (ie, Child-Pugh class A  (<a class="graphic graphic_table graphicRef78401" href="/d/graphic/78401.html" rel="external">table 1</a>)), knowledge of the genotype is not essential to antiviral regimen selection, as the pangenotypic regimens are highly effective in such patients regardless of genotype  (<a class="graphic graphic_algorithm graphicRef93587" href="/d/graphic/93587.html" rel="external">algorithm 1</a>). However, if the genotype is already known, or if checking the genotype does not pose a potential barrier to treatment, knowing that an individual has genotype 3 infection can allow more specific tailoring of the regimen for a subset of those patients, which may increase the likelihood of sustained virologic response (SVR) by a few percentage points.</p><p class="headingAnchor" id="H1397320141"><span class="h4">Known genotype 3 infection</span><span class="headingEndMark"> — </span>For initial treatment of patients with known genotype 3 infection and compensated cirrhosis, the main options are <a class="drug drug_general" data-topicid="114296" href="/d/drug information/114296.html" rel="external">glecaprevir-pibrentasvir</a> and <a class="drug drug_general" data-topicid="108951" href="/d/drug information/108951.html" rel="external">sofosbuvir-velpatasvir</a>  (<a class="graphic graphic_algorithm graphicRef93587" href="/d/graphic/93587.html" rel="external">algorithm 1</a>). In general, we suggest glecaprevir-pibrentasvir because the same eight-week regimen used for other genotypes can be used without additional testing. However, if glecaprevir-pibrentasivr cannot be used (eg, because of unmitigable drug interactions) or if the patient prefers not to use it, a sofosbuvir-velpatasvir-based regimen can be used with resistance testing to inform the optimal administration:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Glecaprevir-pibrentasvir</strong> – This regimen is given for eight weeks. In a single-arm trial of patients with compensated cirrhosis who received this regimen, the SVR rate among the 63 patients with genotype 3 infection was 95 percent [<a href="#rid56">56</a>]. There was only one virologic failure (relapsed infection). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sofosbuvir-velpatasvir</strong><strong>-based regimen</strong> – If a sofosbuvir-velpatasvir-based regimen is planned for initial therapy of genotype 3 infection in a patient with compensated cirrhosis, testing for NS5A resistance-associated substitutions (RASs) should be performed to determine the presence of the Y93H variant, which is associated with treatment failure. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If the Y93H variant is absent, <a class="drug drug_general" data-topicid="108951" href="/d/drug information/108951.html" rel="external">sofosbuvir-velpatasvir</a> is given for 12 weeks. This regimen is estimated to result in SVR rates of 97 percent [<a href="#rid14">14</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If the Y93H variant is present, we use <a class="drug drug_general" data-topicid="114088" href="/d/drug information/114088.html" rel="external">sofosbuvir-velpatasvir-voxilaprevir</a> instead of <a class="drug drug_general" data-topicid="108951" href="/d/drug information/108951.html" rel="external">sofosbuvir-velpatasvir</a>. It is highly effective for patients with cirrhosis [<a href="#rid15">15</a>]; although the optimal duration is uncertain in this setting, 12 weeks is generally recommended [<a href="#rid57">57,58</a>]. An alternative is to add weight-based <a class="drug drug_general" data-topicid="9860" href="/d/drug information/9860.html" rel="external">ribavirin</a> to sofosbuvir-velpatasvir for 12 weeks when the Y93H variant is present to try to improve the suboptimal SVR rate [<a href="#rid59">59</a>]. </p><p></p><p class="bulletIndent2">In the setting of Y93H, SVR rates with <a class="drug drug_general" data-topicid="108951" href="/d/drug information/108951.html" rel="external">sofosbuvir-velpatasvir</a> for 12 weeks are lower than in those without the variant (in one trial, 84 versus 97 percent) [<a href="#rid14">14</a>]. </p><p></p><p>Daclatasvir plus <a class="drug drug_general" data-topicid="91794" href="/d/drug information/91794.html" rel="external">sofosbuvir</a> is an alternative regimen that is not available in the United States but may be used elsewhere when access to other options is limited. However, the optimal duration for patients with cirrhosis is uncertain. We give it for 24 weeks. In a large French cohort, daclatasvir plus sofosbuvir for 24 weeks resulted in SVR rates of approximately 86 percent among patients with genotype 3 infection and cirrhosis [<a href="#rid60">60</a>]. </p><p class="headingAnchor" id="H2210995327"><span class="h4">Unknown or non-genotype 3 infecton</span><span class="headingEndMark"> — </span>For initial treatment of patients with compensated cirrhosis who have genotypes 1, 2, 4, 5, or 6 infection or who have not had genotype assessment, regimen selection and administration are the same as for patients without cirrhosis, as outlined elsewhere. (See <a class="local">'Our preferred regimens'</a> above.)</p><p>Specifically, our preferred regimens include the following. In trials, response rates among patients with compensated cirrhosis were similarly high as in those without cirrhosis:</p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="108951" href="/d/drug information/108951.html" rel="external">Sofosbuvir-velpatasvir</a> for 12 weeks – In a trial of patients with genotype 1, 2, 4, 5, and 6 infection, the SVR rate among the 121 patients with compensated cirrhosis was 99 percent [<a href="#rid11">11</a>]. Other trials have reported similar findings [<a href="#rid12">12-14</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="114296" href="/d/drug information/114296.html" rel="external">Glecaprevir-pibrentasvir</a> for 8 weeks – In a single-arm trial of 343 patients with genotype 1 to 6 infection and compensated cirrhosis, this regimen resulted in an overall SVR rate of 98 percent [<a href="#rid56">56</a>]. Only one patient had virologic failure (relapse of genotype 3 infection). </p><p></p><p>In locations where access to these options is limited, daclatasvir plus <a class="drug drug_general" data-topicid="91794" href="/d/drug information/91794.html" rel="external">sofosbuvir</a> for 24 weeks is a potential alternative; it is not available in the United States. Other alternatives with limited role include <a class="drug drug_general" data-topicid="97562" href="/d/drug information/97562.html" rel="external">ledipasvir-sofosbuvir</a> for 12 weeks for genotypes 1, 4, 5, and 6 infection [<a href="#rid39">39</a>], or <a class="drug drug_general" data-topicid="106574" href="/d/drug information/106574.html" rel="external">elbasvir-grazoprevir</a> for 12 weeks [<a href="#rid47">47,48</a>]. (See <a class="local">'Alternative regimens'</a> above.)</p><p>Overall, data on regimen efficacy for patients who have genotypes 4, 5, or 6 and cirrhosis are limited given the small samples sizes of such patients in clinical trials.</p><p class="headingAnchor" id="H3141680622"><span class="h3">Safety</span><span class="headingEndMark"> — </span>Preferred antiviral regimens have good safety profiles in patients with compensated cirrhosis. </p><p>In trials of <a class="drug drug_general" data-topicid="108951" href="/d/drug information/108951.html" rel="external">sofosbuvir-velpatasvir</a> and <a class="drug drug_general" data-topicid="114296" href="/d/drug information/114296.html" rel="external">glecaprevir-pibrentasvir</a>, adverse effects among those with compensated cirrhosis were similar to those without cirrhosis, and mainly included fatigue, headache, nausea, and diarrhea [<a href="#rid11">11,56,61</a>]. Although reports of hepatic failure with use of other HCV protease inhibitors (eg, boceprevir, <a class="drug drug_general" data-topicid="91660" href="/d/drug information/91660.html" rel="external">simeprevir</a>, paritaprevir-ritonavir) had raised concern for potential toxicity with glecaprevir-pibrentasvir, there does not appear to be an increased risk of drug-induced liver injury or hepatic decompensation with glecaprevir-pibrentasvir among patients with compensated cirrhosis [<a href="#rid61">61</a>]. </p><p class="headingAnchor" id="H2138215699"><span class="h3">Monitoring</span><span class="headingEndMark"> — </span>Monitoring during treatment is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/3673.html" rel="external">"Overview of the management of chronic hepatitis C virus infection", section on 'Monitoring during antiviral therapy'</a>.) </p><p class="headingAnchor" id="H1040331153"><span class="h2">Decompensated cirrhosis (Child-Pugh class B or C)</span><span class="headingEndMark"> — </span>Antiviral treatment should only be undertaken by or in close consultation with an expert in the management of patients with decompensated cirrhosis (eg, Child-Pugh class B or C  (<a class="graphic graphic_table graphicRef78401" href="/d/graphic/78401.html" rel="external">table 1</a>), with ascites, with hepatic encephalopathy, or with gastroesophageal variceal hemorrhage), preferably at a transplant center. The possibility of liver transplantation should be assessed for patients with decompensated cirrhosis or a MELD score greater than 10 prior to initiation of antiviral therapy.</p><p>For individuals who are transplant candidates, the timing of antiviral therapy depends on various factors, including the severity of disease and the expected wait time to transplant. These issues are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/4583.html" rel="external">"Hepatitis C virus infection in liver transplant candidates and recipients", section on 'Deciding to treat before or after transplant'</a>.)</p><p>The outcomes and benefits of antiviral treatment among patients with decompensated cirrhosis are also discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/15832.html" rel="external">"Patient evaluation and selection for antiviral therapy for chronic hepatitis C virus infection", section on 'Decompensated cirrhosis'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antiviral selection</strong> – If antiviral treatment is planned prior to transplant (or for patients who are not transplant candidates), options are limited since certain antiviral agents are contraindicated in the setting of severe hepatic impairment. </p><p></p><p class="bulletIndent1">For initial treatment of any genotype, we suggest: </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="108951" href="/d/drug information/108951.html" rel="external">Sofosbuvir-velpatasvir</a> plus weight-based <a class="drug drug_general" data-topicid="9860" href="/d/drug information/9860.html" rel="external">ribavirin</a> for 12 weeks. In a randomized trial of 267 patients with Child-Pugh class B cirrhosis, SVR rates were 94 percent with sofosbuvir-velpatasvir plus ribavirin for 12 weeks compared with 83 to 86 percent with sofosbuvir-velpatasvir for 12 to 24 weeks; the differences were not statistically significant [<a href="#rid62">62</a>]. SVR rates with sofosbuvir-velpatasvir plus ribavirin were 100 percent for all genotypes except 1a (94 percent) and 3 (85 percent). Results from observational studies are similar [<a href="#rid63">63</a>]. </p><p></p><p class="bulletIndent1">For patients with genotypes 1, 4, 5, or 6, another option is: </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><a class="drug drug_general" data-topicid="97562" href="/d/drug information/97562.html" rel="external">Ledipasvir-sofosbuvir</a> plus weight-based <a class="drug drug_general" data-topicid="9860" href="/d/drug information/9860.html" rel="external">ribavirin</a> for 12 weeks [<a href="#rid64">64,65</a>]. In one trial that randomly assigned patients with decompensated cirrhosis (Child-Pugh class B or C) and creatinine clearance &gt;40 mL/min to receive ledipasvir-sofosbuvir plus ribavirin for 12 or 24 weeks, SVR rates were relatively high (87 to 89 percent) [<a href="#rid64">64</a>]. In another trial of patients with genotypes 1 and 4 infection, ledipasvir-sofosbuvir plus ribavirin for 12 weeks and ledipasvir-sofosbuvir for 24 weeks results in similarly high SVR rates (96 and 97 percent) [<a href="#rid66">66</a>]. </p><p></p><p class="bulletIndent1">For both regimens, the target dose of <a class="drug drug_general" data-topicid="9860" href="/d/drug information/9860.html" rel="external">ribavirin</a> is 1000 mg daily for individuals &lt;75 kg and 1200 mg daily for individuals ≥75 kg. However, because ribavirin may not be optimally tolerated in patients with decompensated cirrhosis, we start ribavirin at a lower dose (eg, 600 mg daily) and increase as tolerated to target dose. If ribavirin cannot be used at all, a 24-week duration of the ribavirin-free regimen is recommended to maximize the likelihood of SVR [<a href="#rid1">1</a>]. However, for genotypes 1 and 2 infection, 12 weeks without ribavirin may be reasonably effective [<a href="#rid62">62,67</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Safety</strong> – Serious adverse events are common in general among patients with decompensated cirrhosis. In trials of <a class="drug drug_general" data-topicid="108951" href="/d/drug information/108951.html" rel="external">sofosbuvir-velpatasvir</a> and ledipasvir-sofosbuvir-based regimens, serious adverse events occurred in 10 to 42 percent, depending on the level of decompensation and on the precise regimen administered, but few were deemed related to the treatment [<a href="#rid62">62,64,65</a>]. </p><p></p><p class="bulletIndent1">In observational studies of patients with decompensated cirrhosis undergoing therapy with contemporary direct-acting antiviral (DAA) regimens, serious adverse events occurred in approximately 20 percent [<a href="#rid63">63,68</a>]. In one cohort, approximately 13 percent had a new decompensating event during or shortly after therapy; hepatic encephalopathy, new ascites, and bacterial peritonitis were reported in 4, 1, and 1 percent [<a href="#rid68">68</a>]. Anemia is also common among these patients, particularly in those receiving <a class="drug drug_general" data-topicid="9860" href="/d/drug information/9860.html" rel="external">ribavirin</a> [<a href="#rid63">63</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monitoring</strong> – Patients with decompensated cirrhosis who are undergoing HCV antiviral therapy should have frequent clinical and laboratory monitoring, including monitoring of liver synthetic function and hemoglobin (particularly if receiving <a class="drug drug_general" data-topicid="9860" href="/d/drug information/9860.html" rel="external">ribavirin</a>). General management issues for patients with decompensated cirrhosis are discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/1263.html" rel="external">"Cirrhosis in adults: Overview of complications, general management, and prognosis", section on 'Major complications'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antiviral agents to avoid </strong>– <a class="drug drug_general" data-topicid="114296" href="/d/drug information/114296.html" rel="external">Glecaprevir-pibrentasvir</a>, <a class="drug drug_general" data-topicid="106574" href="/d/drug information/106574.html" rel="external">elbasvir-grazoprevir</a>, <a class="drug drug_general" data-topicid="114088" href="/d/drug information/114088.html" rel="external">sofosbuvir-velpatasvir-voxilaprevir</a>, and <a class="drug drug_general" data-topicid="91660" href="/d/drug information/91660.html" rel="external">simeprevir</a> are contraindicated in patients with Child-Pugh classes B and C cirrhosis because of increased drug levels in the setting of hepatic impairment. Although they are not available in the United States and of uncertain availability or utility elsewhere, ombitasvir-paritaprevir-ritonavir-based regimens are also contraindicated in patients with Child-Pugh classes B and C cirrhosis because of the risk of worsened hepatic decompensation. </p><p></p><p class="headingAnchor" id="H3149914487"><span class="h1">MANAGEMENT OF MISSED DOSES</span><span class="headingEndMark"> — </span>Given the potency of contemporary antiviral regimens, patients who miss a few doses intermittently do not jeopardize their likelihood of treatment success, and we counsel them to restart and continue the regimen for the originally planned duration (making up for the missed doses). </p><p>The optimal approach to those who miss more than a few consecutive doses is uncertain. We agree with the approach suggested by the joint American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA)  (<a class="graphic graphic_algorithm graphicRef142502" href="/d/graphic/142502.html" rel="external">algorithm 2</a>) [<a href="#rid2">2</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>For those who miss more than 8 but less than 21 consecutive days of therapy: </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Restart the regimen immediately.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Check an HCV viral level as soon as possible (but do not delay therapy restart for this).</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>If the HCV RNA is undetectable, complete the originally planned duration (making up for missed doses). If the patient has compensated cirrhosis or known genotype 3 infection, the guidelines recommend extending the treatment course for another four weeks.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>If the HCV RNA is detectable, next steps depend on how much of the regimen had been completed. Patients who had completed &lt;28 days of therapy prior to missing doses should extend the originally planned duration by four weeks. Patients who had completed ≥28 days of therapy prior to missing doses should stop the current regimen and be evaluated for retreatment. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For those who missed more than 21 consecutive days of therapy, next steps depend on how much of the regimen had been completed. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients who had completed &lt;28 days of therapy prior to missing doses should take the approach outlined above. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients who had completed ≥28 days of therapy prior to missing doses should stop the current regimen and have an HCV viral level checked 12 weeks after the completion of therapy. If HCV RNA is undetectable, they have achieved SVR and do not warrant additional therapy. If HCV RNA is detectable, they should be evaluated for retreatment.</p><p></p><p>The approach to retreatment is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/15795.html" rel="external">"Management of chronic hepatitis C virus infection: Antiviral retreatment following relapse in adults", section on 'Regimen selection for relapse after DAA therapy'</a>.)</p><p>Limited data suggest that minor adherence issues do not have a substantive negative impact on treatment success. In a study of 190 patients who were taking a once- or twice-daily direct-acting antiviral (DAA) regimen, which was dispensed in an electronic blister pack that recorded the time of pill removal, 90 percent missed at least one day of treatment, 48 percent missed between one and eight days of treatment, and 13 percent missed seven or more consecutive days [<a href="#rid69">69</a>]. Although there was a nonsignificant trend towards lower SVR rates among those whose calculated adherence was &lt;90 percent (89 versus 95 percent), there were no differences among those who did nor did not miss at least seven consecutive doses (92 versus 93 percent). Most of the 14 patients who did not achieve SVR had been lost to follow up; only three had virologic failure.</p><p class="headingAnchor" id="H956606846"><span class="h1">SPECIAL PATIENT POPULATIONS</span></p><p class="headingAnchor" id="H16322032"><span class="h2">Patients with renal impairment</span><span class="headingEndMark"> — </span>The selection of HCV antiviral regimens for patients with renal disease is largely the same as that among patients without renal disease. Antiviral treatment in such patients is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/93448.html" rel="external">"Treatment of chronic hepatitis C infection in adults with kidney function impairment"</a>.)</p><p>Additional considerations for patients who are kidney transplant candidates or recipients are also discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/7310.html" rel="external">"Hepatitis C infection in kidney transplant candidates and recipients"</a>.)</p><p class="headingAnchor" id="H1542876419"><span class="h2">HIV-HCV coinfection</span><span class="headingEndMark"> — </span>The selection of HCV antiviral regimens for patient with HIV and HCV coinfection is largely the same as that for patients without HIV infection, although potential interactions between antiretroviral agents and direct-acting antiviral (DAA) agents must be taken into consideration. Treatment of HCV in patients with HIV is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/3701.html" rel="external">"Treatment of chronic hepatitis C virus infection in the patient with HIV"</a>.)</p><p class="headingAnchor" id="H3991501247"><span class="h2">HCV following liver transplantation</span><span class="headingEndMark"> — </span>Management of HCV infection in liver transplant recipients is discussed elsewhere. (See  <a class="medical medical_review" href="/d/html/4583.html" rel="external">"Hepatitis C virus infection in liver transplant candidates and recipients", section on 'Treatment approach for recipients of HCV-viremic donors'</a> and  <a class="medical medical_review" href="/d/html/4583.html" rel="external">"Hepatitis C virus infection in liver transplant candidates and recipients", section on 'Post-transplant antiviral therapy'</a>.)</p><p class="headingAnchor" id="H2295552872"><span class="h2">Pregnant individuals</span><span class="headingEndMark"> — </span>The safety and efficacy of all HCV antiviral agents during pregnancy are unknown; thus, antiviral therapy of such patients should either be delayed until after delivery or be given through a clinical trial. (See  <a class="medical medical_review" href="/d/html/3637.html" rel="external">"Vertical transmission of hepatitis C virus"</a>.)</p><p class="headingAnchor" id="H2678293065"><span class="h1">FOLLOW-UP AFTER TREATMENT</span><span class="headingEndMark"> — </span>Follow-up after treatment includes checking the viral load 12 weeks after the cessation of therapy to evaluate for a sustained virologic response (SVR). Patients with advanced fibrosis or cirrhosis also warrant ongoing screening for hepatocellular carcinoma, regardless of antiviral treatment outcome. These issues are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/3673.html" rel="external">"Overview of the management of chronic hepatitis C virus infection", section on 'Follow-up after antiviral therapy'</a>.)</p><p class="headingAnchor" id="H1231582976"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/d/html/113060.html" rel="external">"Society guideline links: Hepatitis C virus infection"</a>.)</p><p class="headingAnchor" id="H148836731"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/d/html/86452.html" rel="external">"Patient education: Treatment for hepatitis C (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H148836809"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Benefits of HCV therapy</strong> – We recommend antiviral treatment for all patients with chronic HCV infection (<a class="grade" href="https://medilib.ir/uptodate/show/grade_1" rel="external">Grade 1A</a>). A sustained virologic response (SVR), or an undetectable HCV viral level 12 weeks after the completion of therapy, indicates effective cure of HCV infection. SVR has been associated with decreased mortality, decreased liver-related complications, and improved quality of life, regardless of liver disease stage. (See <a class="local">'Treatment objective'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prioritizing access to therapy</strong> – Extensive pretreatment testing or monitoring may unnecessarily limit access to therapy in resource-constrained settings or by nonspecialty providers. Given the high efficacy rates and safety of contemporary pangenotypic antiviral regimens for initial therapy of HCV infection, we instead favor a streamlined approach to regimen selection with limited pretreatment evaluation, a minimalist approach to monitoring, and a low threshold to offer therapy despite unstable housing or drug use. (See <a class="local">'Prioritizing access to therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation</strong> <strong>prior to initial therapy</strong> – Limited evaluation includes clinical assessment for cirrhosis, testing for other conditions that may impact management, such as HIV, hepatitis B virus (HBV), and pregnancy, and a review of the medication list for potential interactions. Since genotype is not essential for regimen selection, we do not routinely check it; lack of genotype testing results should not be a barrier to HCV treatment. (See <a class="local">'Limited pretreatment evaluation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Preferred regimens</strong> – For initial therapy, we suggest one of the pangenotypic regimens, <a class="drug drug_general" data-topicid="108951" href="/d/drug information/108951.html" rel="external">sofosbuvir-velpatasvir</a> or <a class="drug drug_general" data-topicid="114296" href="/d/drug information/114296.html" rel="external">glecaprevir-pibrentasvir</a>, rather than other regimens  (<a class="graphic graphic_algorithm graphicRef93587" href="/d/graphic/93587.html" rel="external">algorithm 1</a>) (<a class="grade" href="https://medilib.ir/uptodate/show/grade_4" rel="external">Grade 2A</a>). Sofosbuvir-velpatasvir is given for 12 weeks and glecaprevir-pibrentasvir for 8 weeks; these regimens result in SVR rates &gt;95 percent with any genotype and have minor adverse effects. The choice between them depends on availability, potential for drug interactions, and patient preference. (See <a class="local">'Selecting among preferred regimens'</a> above.)</p><p></p><p class="bulletIndent1">Non-pangenotypic regimens are also effective but offer no clear advantage over the pangenotypic regimens, and using them optimally may require additional testing that could be a barrier to care. Their main role is in locations where <a class="drug drug_general" data-topicid="108951" href="/d/drug information/108951.html" rel="external">sofosbuvir-velpatasvir</a> or <a class="drug drug_general" data-topicid="114296" href="/d/drug information/114296.html" rel="external">glecaprevir-pibrentasvir</a> is not available. Internationally, the most widely used alternative regimen is <a class="drug drug_general" data-topicid="91794" href="/d/drug information/91794.html" rel="external">sofosbuvir</a> plus daclatasvir, which is given for 12 or 24 weeks for patients without or with cirrhosis, respectively. (See <a class="local">'Alternative regimens'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Managing drug interactions</strong> – Drug interactions with <a class="drug drug_general" data-topicid="108951" href="/d/drug information/108951.html" rel="external">sofosbuvir-velpatasvir</a> or <a class="drug drug_general" data-topicid="114296" href="/d/drug information/114296.html" rel="external">glecaprevir-pibrentasvir</a> are generally manageable but should be evaluated prior to initiation. Increased gastric pH levels decrease absorption of velpatasvir; thus, we avoid coadministration of sofosbuvir-velpatasvir with proton pump inhibitors and other acid-reducing medications (including over-the-counter medications) when possible. For other specific drug interactions, refer to the <a class="external" href="/drug-interactions">drug interactions program</a> included with UpToDate. (See <a class="local">'Sofosbuvir-velpatasvir'</a> above and <a class="local">'Glecaprevir-pibrentasvir'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monitoring</strong> – Typical monitoring includes evaluation for rare adverse effects and adherence assessment throughout the treatment course. This is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/3673.html" rel="external">"Overview of the management of chronic hepatitis C virus infection", section on 'Monitoring during antiviral therapy'</a>.)</p><p></p><p class="bulletIndent1">However, for patients who take one of the preferred regimens and have no cirrhosis, active HBV infection, concerning symptoms, or potential drug interactions, we suggest minimal monitoring without planned visits or laboratory testing during the antiviral course. (See <a class="local">'Potential for minimal monitoring during treatment'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Missed doses</strong> – We counsel patients who miss a few doses intermittently (eg, fewer than seven) to restart and continue the regimen for the originally planned duration (making up for the missed doses). For those who have missed more, the approach depends on how many doses they missed and how far into the treatment course they are  (<a class="graphic graphic_algorithm graphicRef142502" href="/d/graphic/142502.html" rel="external">algorithm 2</a>). (See <a class="local">'Management of missed doses'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Post-treatment follow-up</strong> – All patients should undergo HCV viral level testing at least 12 weeks after completing therapy to assess for treatment success. Patients with advanced fibrosis or cirrhosis warrant ongoing surveillance for hepatocellular carcinoma. These and other aspects of follow-up are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/3673.html" rel="external">"Overview of the management of chronic hepatitis C virus infection", section on 'Follow-up after antiviral therapy'</a>.)</p><p></p><p class="headingAnchor" id="H332115496"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Sanjiv Chopra, MD, MACP, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Recommendations for Testing, Managing, and Treating Hepatitis C. Joint panel from the American Association of the Study of Liver Diseases and the Infectious Diseases Society of America. http://www.hcvguidelines.org/ (Accessed on July 01, 2023).</li><li><a class="nounderline abstract_t">Bhattacharya D, Aronsohn A, Price J, et al. Hepatitis C Guidance 2023 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection. Clin Infect Dis 2023.</a></li><li><a class="nounderline abstract_t">Simmons B, Saleem J, Hill A, et al. Risk of Late Relapse or Reinfection With Hepatitis C Virus After Achieving a Sustained Virological Response: A Systematic Review and Meta-analysis. Clin Infect Dis 2016; 62:683.</a></li><li><a class="nounderline abstract_t">Solomon SS, Wagner-Cardoso S, Smeaton L, et al. A minimal monitoring approach for the treatment of hepatitis C virus infection (ACTG A5360 [MINMON]): a phase 4, open-label, single-arm trial. Lancet Gastroenterol Hepatol 2022; 7:307.</a></li><li><a class="nounderline abstract_t">Kattakuzhy S, Gross C, Emmanuel B, et al. Expansion of Treatment for Hepatitis C Virus Infection by Task Shifting to Community-Based Nonspecialist Providers: A Nonrandomized Clinical Trial. Ann Intern Med 2017; 167:311.</a></li><li><a class="nounderline abstract_t">Hunt BR, Cetrone H, Sam S, Glick NR. Outcomes of a Pharmacist-Led Hepatitis C Virus Treatment Program in an Urban Safety-Net Health System, Chicago, 2017-2019. Public Health Rep 2022; 137:702.</a></li><li><a class="nounderline abstract_t">Dore GJ, Feld JJ, Thompson A, et al. Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial. J Hepatol 2020; 72:431.</a></li><li><a class="nounderline abstract_t">Graf C, Mücke MM, Dultz G, et al. Efficacy of Direct-acting Antivirals for Chronic Hepatitis C Virus Infection in People Who Inject Drugs or Receive Opioid Substitution Therapy: A Systematic Review and Meta-analysis. Clin Infect Dis 2020; 70:2355.</a></li><li class="breakAll">Rodriguez-Reyes M, Sotoca JM, and Soy-Muner D. Successful sofosbuvir/velpatasvir treatment in a hepatitis C patient receiving chronic antiepileptic therapy: a case report. European Journal of Hospital Pharmacy. https://ejhp.bmj.com/content/29/Suppl_1/A46.1 (Accessed on June 19, 2023).</li><li><a class="nounderline abstract_t">Kempker RR, Alghamdi WA, Al-Shaer MH, et al. A Pharmacology Perspective of Simultaneous Tuberculosis and Hepatitis C Treatment. Antimicrob Agents Chemother 2019; 63.</a></li><li><a class="nounderline abstract_t">Feld JJ, Jacobson IM, Hézode C, et al. Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection. N Engl J Med 2015; 373:2599.</a></li><li><a class="nounderline abstract_t">Everson GT, Towner WJ, Davis MN, et al. Sofosbuvir With Velpatasvir in Treatment-Naive Noncirrhotic Patients With Genotype 1 to 6 Hepatitis C Virus Infection: A Randomized Trial. Ann Intern Med 2015; 163:818.</a></li><li><a class="nounderline abstract_t">Pianko S, Flamm SL, Shiffman ML, et al. Sofosbuvir Plus Velpatasvir Combination Therapy for Treatment-Experienced Patients With Genotype 1 or 3 Hepatitis C Virus Infection: A Randomized Trial. Ann Intern Med 2015; 163:809.</a></li><li><a class="nounderline abstract_t">Foster GR, Afdhal N, Roberts SK, et al. Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection. N Engl J Med 2015; 373:2608.</a></li><li><a class="nounderline abstract_t">Jacobson IM, Lawitz E, Gane EJ, et al. Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials. Gastroenterology 2017; 153:113.</a></li><li><a class="nounderline abstract_t">Wei L, Lim SG, Xie Q, et al. Sofosbuvir-velpatasvir for treatment of chronic hepatitis C virus infection in Asia: a single-arm, open-label, phase 3 trial. Lancet Gastroenterol Hepatol 2019; 4:127.</a></li><li><a class="nounderline abstract_t">Kateera F, Shumbusho F, Manirambona L, et al. Safety and efficacy of sofosbuvir-velpatasvir to treat chronic hepatitis C virus infection in treatment-naive patients in Rwanda (SHARED-3): a single-arm trial. Lancet Gastroenterol Hepatol 2022; 7:533.</a></li><li><a class="nounderline abstract_t">Mangia A, Milligan S, Khalili M, et al. Global real-world evidence of sofosbuvir/velpatasvir as simple, effective HCV treatment: Analysis of 5552 patients from 12 cohorts. Liver Int 2020; 40:1841.</a></li><li class="breakAll">Epclusa (sofosbuvir and velpatasvir). US FDA approved product information. National Library of Medicine. www.dailymed.nlm.nih.gov.</li><li class="breakAll">Jacobson IM, Brau N, Bourgeois S, et al. The tolerability of sofosbuvir/velpatasvir for 12 Weeks in &gt;1000 patients treated in the ASTRAL-1, ASTRAL-2, and ASTRAL-3 studies: An integrated safety analysis. Presented at the 51st Annual Meeting of the European Association for the Study of the Liver (EASL), Barcelona, Spain, April 13-17, 2016.
</li><li><a class="nounderline abstract_t">Zeuzem S, Foster GR, Wang S, et al. Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection. N Engl J Med 2018; 378:354.</a></li><li class="breakAll">Puoti M, Foster GR, Wang S, et al. High SVR Rates With Eight and Twelve Weeks of Pangenotypic Glecaprevir/Pibrentasvir: Integrated Efficacy Analysis of Genotype 1-6 Patients Without Cirrhosis. Presented at the 52nd Annual Meeting of the European Association for the Study of the Liver (EASL), Amsterdam, The Netherlands, April 19-23, 2017.</li><li><a class="nounderline abstract_t">Kwo PY, Poordad F, Asatryan A, et al. Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis. J Hepatol 2017; 67:263.</a></li><li><a class="nounderline abstract_t">Forns X, Lee SS, Valdes J, et al. Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial. Lancet Infect Dis 2017; 17:1062.</a></li><li class="breakAll">Hassanein T, Wyles D, Wang S, et al. SURVEYOR-II, Part 4: Glecaprevir/Pibrentasvir [ABT493+ABT530] Demonstrates High SVR Rates in Patients With HCV Genotype 2, 4, 5, or 6 Infection Without Cirrhosis Following an 8-Week Treatment Duration. Presented at the American Association for the Study of Liver Diseases Liver Meeting, Boston, MA, November 11-15, 2016.</li><li><a class="nounderline abstract_t">Asselah T, Kowdley KV, Zadeikis N, et al. Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis. Clin Gastroenterol Hepatol 2018; 16:417.</a></li><li><a class="nounderline abstract_t">Naganuma A, Chayama K, Notsumata K, et al. Integrated analysis of 8-week glecaprevir/pibrentasvir in Japanese and overseas patients without cirrhosis and with hepatitis C virus genotype 1 or 2 infection. J Gastroenterol 2019; 54:752.</a></li><li><a class="nounderline abstract_t">Lampertico P, Carrión JA, Curry M, et al. Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of patients with chronic HCV infection: A meta-analysis. J Hepatol 2020; 72:1112.</a></li><li><a class="nounderline abstract_t">Cornberg M, Stoehr A, Naumann U, et al. Real-World Safety, Effectiveness, and Patient-Reported Outcomes in Patients with Chronic Hepatitis C Virus Infection Treated with Glecaprevir/Pibrentasvir: Updated Data from the German Hepatitis C-Registry (DHC-R). Viruses 2022; 14.</a></li><li><a class="nounderline abstract_t">D'Ambrosio R, Pasulo L, Puoti M, et al. Real-world effectiveness and safety of glecaprevir/pibrentasvir in 723 patients with chronic hepatitis C. J Hepatol 2019; 70:379.</a></li><li><a class="nounderline abstract_t">Puoti M, Foster GR, Wang S, et al. High SVR12 with 8-week and 12-week glecaprevir/pibrentasvir therapy: An integrated analysis of HCV genotype 1-6 patients without cirrhosis. J Hepatol 2018; 69:293.</a></li><li><a class="nounderline abstract_t">Wei L, Wang G, Alami NN, et al. Glecaprevir-pibrentasvir to treat chronic hepatitis C virus infection in Asia: two multicentre, phase 3 studies- a randomised, double-blind study (VOYAGE-1) and an open-label, single-arm study (VOYAGE-2). Lancet Gastroenterol Hepatol 2020; 5:839.</a></li><li class="breakAll">Dufour JF, Zuckerman E, Zadeikis N, et al. Safety of Glecaprevir/Pibrentasvir in Adults With Chronic Genotype 1-6  Hepatitis C Virus Infection: An Integrated Analysis. Presented at the 52nd Annual Meeting of the European Association for the Study of the Liver (EASL), Amsterdam, The Netherlands, April 19-23, 2017.</li><li><a class="nounderline abstract_t">Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med 2014; 370:211.</a></li><li><a class="nounderline abstract_t">Wyles DL, Ruane PJ, Sulkowski MS, et al. Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1. N Engl J Med 2015; 373:714.</a></li><li><a class="nounderline abstract_t">Nelson DR, Cooper JN, Lalezari JP, et al. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology 2015; 61:1127.</a></li><li><a class="nounderline abstract_t">Belperio PS, Shahoumian TA, Loomis TP, et al. Real-world effectiveness of daclatasvir plus sofosbuvir and velpatasvir/sofosbuvir in hepatitis C genotype 2 and 3. J Hepatol 2019; 70:15.</a></li><li><a class="nounderline abstract_t">Mangia A, Arleo A, Copetti M, et al. The combination of daclatasvir and sofosbuvir for curing genotype 2 patients who cannot tolerate ribavirin. Liver Int 2016; 36:971.</a></li><li><a class="nounderline abstract_t">Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 2014; 370:1889.</a></li><li><a class="nounderline abstract_t">Kowdley KV, Gordon SC, Reddy KR, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med 2014; 370:1879.</a></li><li><a class="nounderline abstract_t">Lawitz E, Poordad FF, Pang PS, et al. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial. Lancet 2014; 383:515.</a></li><li><a class="nounderline abstract_t">Gane EJ, Stedman CA, Hyland RH, et al. Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection. Gastroenterology 2014; 146:736.</a></li><li><a class="nounderline abstract_t">Mizokami M, Yokosuka O, Takehara T, et al. Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial. Lancet Infect Dis 2015; 15:645.</a></li><li><a class="nounderline abstract_t">Terrault NA, Zeuzem S, Di Bisceglie AM, et al. Effectiveness of Ledipasvir-Sofosbuvir Combination in Patients With Hepatitis C Virus Infection and Factors Associated With Sustained Virologic Response. Gastroenterology 2016; 151:1131.</a></li><li><a class="nounderline abstract_t">Buggisch P, Vermehren J, Mauss S, et al. Real-world effectiveness of 8-week treatment with ledipasvir/sofosbuvir in chronic hepatitis C. J Hepatol 2018; 68:663.</a></li><li><a class="nounderline abstract_t">Kowdley KV, Sundaram V, Jeon CY, et al. Eight weeks of ledipasvir/sofosbuvir is effective for selected patients with genotype 1 hepatitis C virus infection. Hepatology 2017; 65:1094.</a></li><li><a class="nounderline abstract_t">Zeuzem S, Ghalib R, Reddy KR, et al. Grazoprevir-Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection: A Randomized Trial. Ann Intern Med 2015; 163:1.</a></li><li><a class="nounderline abstract_t">Lawitz E, Gane E, Pearlman B, et al. Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial. Lancet 2015; 385:1075.</a></li><li><a class="nounderline abstract_t">Buti M, Gordon SC, Zuckerman E, et al. Grazoprevir, Elbasvir, and Ribavirin for Chronic Hepatitis C Virus Genotype 1 Infection After Failure of Pegylated Interferon and Ribavirin With an Earlier-Generation Protease Inhibitor: Final 24-Week Results From C-SALVAGE. Clin Infect Dis 2016; 62:32.</a></li><li><a class="nounderline abstract_t">Sulkowski M, Hezode C, Gerstoft J, et al. Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial. Lancet 2015; 385:1087.</a></li><li class="breakAll">Jacobson, F Poordad, R Firpi-Morell, et al. Efficacy and safety af grazoprevir and elbasvir in hepatitis C genotype 1-infected patients with Child-Pugh class B cirrhosis (C-SALT Part A). Presented at the 2015 International Liver Congress: 50th Annual Meeting of the European Association for the Study of the Liver (EASL). Vienna, April 22-26, 2015. Abstract O008. </li><li class="breakAll">Dore G, Altice F, Litwin AH, et al. C-EDGE CO-STAR: Efficacy of grazoprevir and elbasvir in persons who inject drugs (PWID) receiving opioid agonist therapy. Presented at the American Association for the Study of Liver Diseases Liver Meeting, San Francisco CA, November 13-17, 2015. Abstract #40.</li><li class="breakAll">D Roth, D Nelson, A Bruchfeld, et al. C-SURFER: grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and chronic kidney disease. Presented at the 2015 International Liver Congress: 50th Annual Meeting of the European Association for the Study of the Liver (EASL). Vienna, April 22-26, 2015. Abstract LP02.</li><li><a class="nounderline abstract_t">Huang CF, Hung CH, Cheng PN, et al. An Open-Label, Randomized, Active-Controlled Trial of 8 Versus 12 Weeks of Elbasvir/Grazoprevir for Treatment-Naive Patients With Chronic Hepatitis C Genotype 1b Infection and Mild Fibrosis (EGALITE Study): Impact of Baseline Viral Loads and NS5A Resistance-Associated Substitutions. J Infect Dis 2019; 220:557.</a></li><li class="breakAll">Asselah T, Reesink HW, Gerstoft J, et al. High efficacy of grazoprevir and elbasvir with or without ribavirin in 103 treatment-naive and experienced patients with HCV genotype 4 infection: A pooled analysis. Presented at the American Association for the Study of Liver Diseases Liver Meeting, San Francisco CA, November 13-17, 2015. Abstract #251.</li><li><a class="nounderline abstract_t">Brown RS Jr, Buti M, Rodrigues L, et al. Glecaprevir/pibrentasvir for 8 weeks in treatment-naïve patients with chronic HCV genotypes 1-6 and compensated cirrhosis: The EXPEDITION-8 trial. J Hepatol 2020; 72:441.</a></li><li class="breakAll">Recommendations for Testing, Managing, and Treating Hepatitis C. Joint panel from the American Association of the Study of Liver Diseases and the Infectious Diseases Society of America. http://www.hcvguidelines.org/ (Accessed on July 08, 2016).</li><li><a class="nounderline abstract_t">European Association for the Study of the Liver. Electronic address: <span class="__cf_email__" data-cfemail="0f6a6e7c63606969666c6a4f6a6e7c63606969666c6a216a7a">[email protected]</span>, European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2018. J Hepatol 2018; 69:461.</a></li><li><a class="nounderline abstract_t">Esteban R, Pineda JA, Calleja JL, et al. Efficacy of Sofosbuvir and Velpatasvir, With and Without Ribavirin, in Patients With Hepatitis C Virus Genotype 3 Infection and Cirrhosis. Gastroenterology 2018; 155:1120.</a></li><li><a class="nounderline abstract_t">Hézode C, Lebray P, De Ledinghen V, et al. Daclatasvir plus sofosbuvir, with or without ribavirin, for hepatitis C virus genotype 3 in a French early access programme. Liver Int 2017; 37:1314.</a></li><li><a class="nounderline abstract_t">Gane E, Poordad F, Zadeikis N, et al. Safety and Pharmacokinetics of Glecaprevir/Pibrentasvir in Adults With Chronic Genotype 1-6 Hepatitis C Virus Infections and Compensated Liver Disease. Clin Infect Dis 2019; 69:1657.</a></li><li><a class="nounderline abstract_t">Curry MP, O'Leary JG, Bzowej N, et al. Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis. N Engl J Med 2015; 373:2618.</a></li><li><a class="nounderline abstract_t">Liu CH, Chen CY, Su WW, et al. Sofosbuvir/velpatasvir plus ribavirin for Child-Pugh B and Child-Pugh C hepatitis C virus-related cirrhosis. Clin Mol Hepatol 2021; 27:575.</a></li><li><a class="nounderline abstract_t">Charlton M, Everson GT, Flamm SL, et al. Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease. Gastroenterology 2015; 149:649.</a></li><li><a class="nounderline abstract_t">Manns M, Samuel D, Gane EJ, et al. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. Lancet Infect Dis 2016; 16:685.</a></li><li><a class="nounderline abstract_t">Bourlière M, Bronowicki JP, de Ledinghen V, et al. Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS). Lancet Infect Dis 2015; 15:397.</a></li><li><a class="nounderline abstract_t">Tada T, Kurosaki M, Nakamura S, et al. Real-world clinical outcomes of sofosbuvir and velpatasvir treatment in HCV genotype 1- and 2-infected patients with decompensated cirrhosis: A nationwide multicenter study by the Japanese Red Cross Liver Study Group. J Med Virol 2021; 93:6247.</a></li><li><a class="nounderline abstract_t">Verna EC, Morelli G, Terrault NA, et al. DAA therapy and long-term hepatic function in advanced/decompensated cirrhosis: Real-world experience from HCV-TARGET cohort. J Hepatol 2020; 73:540.</a></li><li><a class="nounderline abstract_t">Cunningham EB, Hajarizadeh B, Amin J, et al. Adherence to Once-daily and Twice-daily Direct-acting Antiviral Therapy for Hepatitis C Infection Among People With Recent Injection Drug Use or Current Opioid Agonist Therapy. Clin Infect Dis 2020; 71:e115.</a></li></ol></div><div id="topicVersionRevision">Topic 16592 Version 93.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="http://www.hcvguidelines.org/" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Recommendations for Testing, Managing, and Treating Hepatitis C. Joint panel from the American Association of the Study of Liver Diseases and the Infectious Diseases Society of America. http://www.hcvguidelines.org/ (Accessed on July 01, 2023).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37229695" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Hepatitis C Guidance 2023 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26787172" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Risk of Late Relapse or Reinfection With Hepatitis C Virus After Achieving a Sustained Virological Response: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35026142" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : A minimal monitoring approach for the treatment of hepatitis C virus infection (ACTG A5360 [MINMON]): a phase 4, open-label, single-arm trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28785771" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Expansion of Treatment for Hepatitis C Virus Infection by Task Shifting to Community-Based Nonspecialist Providers: A Nonrandomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34043923" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Outcomes of a Pharmacist-Led Hepatitis C Virus Treatment Program in an Urban Safety-Net Health System, Chicago, 2017-2019.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31655134" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31513710" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Efficacy of Direct-acting Antivirals for Chronic Hepatitis C Virus Infection in People Who Inject Drugs or Receive Opioid Substitution Therapy: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31513710" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Efficacy of Direct-acting Antivirals for Chronic Hepatitis C Virus Infection in People Who Inject Drugs or Receive Opioid Substitution Therapy: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31591118" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : A Pharmacology Perspective of Simultaneous Tuberculosis and Hepatitis C Treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26571066" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Sofosbuvir and Velpatasvir for HCV Genotype 1, 2, 4, 5, and 6 Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26551051" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Sofosbuvir With Velpatasvir in Treatment-Naive Noncirrhotic Patients With Genotype 1 to 6 Hepatitis C Virus Infection: A Randomized Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26551263" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Sofosbuvir Plus Velpatasvir Combination Therapy for Treatment-Experienced Patients With Genotype 1 or 3 Hepatitis C Virus Infection: A Randomized Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26575258" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28390869" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30555048" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Sofosbuvir-velpatasvir for treatment of chronic hepatitis C virus infection in Asia: a single-arm, open-label, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35248213" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Safety and efficacy of sofosbuvir-velpatasvir to treat chronic hepatitis C virus infection in treatment-naive patients in Rwanda (SHARED-3): a single-arm trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32449966" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Global real-world evidence of sofosbuvir/velpatasvir as simple, effective HCV treatment: Analysis of 5552 patients from 12 cohorts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32449966" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Global real-world evidence of sofosbuvir/velpatasvir as simple, effective HCV treatment: Analysis of 5552 patients from 12 cohorts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32449966" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Global real-world evidence of sofosbuvir/velpatasvir as simple, effective HCV treatment: Analysis of 5552 patients from 12 cohorts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29365309" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29365309" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28412293" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1-6 without cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28818546" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28818546" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28951228" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Efficacy of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Patients With Hepatitis C Virus Genotype 2, 4, 5, or 6 Infection Without Cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30868245" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Integrated analysis of 8-week glecaprevir/pibrentasvir in Japanese and overseas patients without cirrhosis and with hepatitis C virus genotype 1 or 2 infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32061651" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Real-world effectiveness and safety of glecaprevir/pibrentasvir for the treatment of patients with chronic HCV infection: A meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35891520" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Real-World Safety, Effectiveness, and Patient-Reported Outcomes in Patients with Chronic Hepatitis C Virus Infection Treated with Glecaprevir/Pibrentasvir: Updated Data from the German Hepatitis C-Registry (DHC-R).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30472321" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Real-world effectiveness and safety of glecaprevir/pibrentasvir in 723 patients with chronic hepatitis C.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29551706" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : High SVR12 with 8-week and 12-week glecaprevir/pibrentasvir therapy: An integrated analysis of HCV genotype 1-6 patients without cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32682494" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Glecaprevir-pibrentasvir to treat chronic hepatitis C virus infection in Asia: two multicentre, phase 3 studies- a randomised, double-blind study (VOYAGE-1) and an open-label, single-arm study (VOYAGE-2).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32682494" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Glecaprevir-pibrentasvir to treat chronic hepatitis C virus infection in Asia: two multicentre, phase 3 studies- a randomised, double-blind study (VOYAGE-1) and an open-label, single-arm study (VOYAGE-2).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24428467" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26196502" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25614962" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30266283" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Real-world effectiveness of daclatasvir plus sofosbuvir and velpatasvir/sofosbuvir in hepatitis C genotype 2 and 3.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26786792" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : The combination of daclatasvir and sofosbuvir for curing genotype 2 patients who cannot tolerate ribavirin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24725239" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24720702" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24209977" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24262278" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25863559" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27565882" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Effectiveness of Ledipasvir-Sofosbuvir Combination in Patients With Hepatitis C Virus Infection and Factors Associated With Sustained Virologic Response.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29133244" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Real-world effectiveness of 8-week treatment with ledipasvir/sofosbuvir in chronic hepatitis C.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28027579" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Eight weeks of ledipasvir/sofosbuvir is effective for selected patients with genotype 1 hepatitis C virus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25909356" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Grazoprevir-Elbasvir Combination Therapy for Treatment-Naive Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis C Virus Genotype 1, 4, or 6 Infection: A Randomized Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25467591" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26371152" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Grazoprevir, Elbasvir, and Ribavirin for Chronic Hepatitis C Virus Genotype 1 Infection After Failure of Pegylated Interferon and Ribavirin With an Earlier-Generation Protease Inhibitor: Final 24-Week Results From C-SALVAGE.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25467560" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25467560" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25467560" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25467560" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30957170" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : An Open-Label, Randomized, Active-Controlled Trial of 8 Versus 12 Weeks of Elbasvir/Grazoprevir for Treatment-Naive Patients With Chronic Hepatitis C Genotype 1b Infection and Mild Fibrosis (EGALITE Study): Impact of Baseline Viral Loads and NS5A Resistance-Associated Substitutions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30957170" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : An Open-Label, Randomized, Active-Controlled Trial of 8 Versus 12 Weeks of Elbasvir/Grazoprevir for Treatment-Naive Patients With Chronic Hepatitis C Genotype 1b Infection and Mild Fibrosis (EGALITE Study): Impact of Baseline Viral Loads and NS5A Resistance-Associated Substitutions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31682879" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Glecaprevir/pibrentasvir for 8 weeks in treatment-naïve patients with chronic HCV genotypes 1-6 and compensated cirrhosis: The EXPEDITION-8 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31682879" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Glecaprevir/pibrentasvir for 8 weeks in treatment-naïve patients with chronic HCV genotypes 1-6 and compensated cirrhosis: The EXPEDITION-8 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29650333" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : EASL Recommendations on Treatment of Hepatitis C 2018.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29958855" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Efficacy of Sofosbuvir and Velpatasvir, With and Without Ribavirin, in Patients With Hepatitis C Virus Genotype 3 Infection and Cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28177199" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Daclatasvir plus sofosbuvir, with or without ribavirin, for hepatitis C virus genotype 3 in a French early access programme.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30923816" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Safety and Pharmacokinetics of Glecaprevir/Pibrentasvir in Adults With Chronic Genotype 1-6 Hepatitis C Virus Infections and Compensated Liver Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26569658" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Sofosbuvir and Velpatasvir for HCV in Patients with Decompensated Cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34255961" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Sofosbuvir/velpatasvir plus ribavirin for Child-Pugh B and Child-Pugh C hepatitis C virus-related cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25985734" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26907736" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25773757" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34170517" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Real-world clinical outcomes of sofosbuvir and velpatasvir treatment in HCV genotype 1- and 2-infected patients with decompensated cirrhosis: A nationwide multicenter study by the Japanese Red Cross Liver Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32243960" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : DAA therapy and long-term hepatic function in advanced/decompensated cirrhosis: Real-world experience from HCV-TARGET cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31677262" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Adherence to Once-daily and Twice-daily Direct-acting Antiviral Therapy for Hepatitis C Infection Among People With Recent Injection Drug Use or Current Opioid Agonist Therapy.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
